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INTRODUCTION: Much evidence indicates the importance of the endothelium and hypercholesterolemia in atherosclerosis, as 
well as the decline in endothelial function with aging. However, it is unclear if treating dyslipidemia in elderly patients improves 
endothelial function and reduces C-reactive protein levels.
OBJECTIVES: To evaluate vasomotor function, lipids and C-reactive protein in mildly hypertensive and hypercholesterolemic 
elderly patients treated with atorvastatin.
METHODS: Forty-seven elderly Brazilian subjects (≥ 65 years old) with LDL cholesterol (LDL-c) ≥ 130 mg/dL were randomly 
assigned, in a double-blinded manner, to receive either placebo (n = 23) or 20 mg/day of atorvastatin (n = 24) for 4 weeks. Exclu-
sion criteria included diabetes, serious hypertension, obesity, steroid use, hormone replacement, and statin use within the previous 
six months. All patients underwent clinical examinations, laboratory tests (glucose, lipids, liver enzymes, creatine phosphokinase 
and high sensitivity C-reactive protein) and assessment of vasomotor function by high-resolution ultrasound examination of the 
brachial artery (flow-mediated dilation and sublingual nitrate), both before and after treatment. 
RESULTS: The patients were 65 to 91 years old; there was no significant difference between basal flow-mediated dilation of 
placebo (7.3 ± 6.1%) and atorvastatin (4.5 ± 5.1%; p = 0.20). The same was observed after treatment (6.6 ± 6.2 vs. 5.0 ± 5.6; p 
= 0.55). The initial nitrate dilatation (8.1 ± 5.4% vs. 10.8 ± 7.5%; p = 0.24) and that after 4 week treatment (7.1 ± 4.7% vs. 8.6 ± 
5.0%; p = 0.37) were similar. Atorvastatin produced a reduction of 20% of the C-reactive protein and 42% in the LDL-c; however, 
there were no changes in the flow-mediated dilation.
CONCLUSIONS: Atorvastatin produced a significant change of lipids and C-reactive protein; however, there were no changes in 
vasomotor function, suggesting the existence of intrinsic age-related vessel alterations.
KEYWORDS: Endothelium/ultrasonography; Aged; Hydroximetilglutaril-CoA reductase inhibitors; C-reactive protein; Lipid. 
INTRODUCTION
Life expectancy is increasing all over the world, and 
similar rates are now observed in both developed and in 
developing countries. Aging is associated with several 
biological alterations in all body systems and it is associated 
with a high prevalence of cardiovascular diseases, which 
result in greater rates of hospitalization, disability and 
death.1-4 Aging is an independent risk factor for coronary 
disease1,2 and is associated with arterial stiffness and 
left ventricular diastolic dysfunction, which may be 
responsible for symptoms such as dyspnea, fatigue and 
arterial hypertension.3-5 In addition to intrinsic alterations 
of the arterial wall, there is a decline of endothelial function 
with aging.6-12 When dyslipidemia occurs in the elderly, 
an additional mechanism may contribute to the reduced 
vasodilatory capacity of the arteries. However, it is not clear 
to what extent dyslipidemia contributes to such dysfunction. 
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Previous studies have reported restoration of endothelial 
function and reduction of C-reactive protein (CRP) levels 
with the use of statins in individuals with risk factors for 
coronary arterial disease.13,14 However, it has not been clearly 
established whether treating dyslipidemia in elderly people 
actually improves vasomotor function and reduces CRP. 
The objective of this study was to evaluate the 
endothelium-dependent and -independent vasodilatory 
response, lipid levels and CRP in mildly hypertensive 
hypercholesterolemic but otherwise “healthy” elderly 
individuals treated with atorvastatin.
METHODS
We evaluated 419 elderly people, defined as being ≥ 65 
years old, using questionnaires and medical appointments 
conducted during 2005, at the outpatient clinic of a 
University Hospital of Salvador, Bahia, Brazil. Of these, 
we selected 72 patients considered to be “healthy;” 47 of 
them had LDL cholesterol (LDL-c) ≥ 130 mg/dL and were 
randomized to receive either atorvastatin (20 mg) or placebo, 
in a double-blind randomized placebo-controlled trial. The 
exclusion criteria included: diabetes, serious hypertension 
(systolic pressure > 190 mm Hg and diastolic pressure > 
110 mm Hg), obesity (BMI ≥ 30 g/m2), heavy smoking, 
steroid use, hormone replacement therapy, alcoholism, 
kidney diseases (serum creatinine > 2 mg/dL), liver diseases, 
thyroid diseases and end-stage disease, manifest coronary 
disease, previous stroke, ejection fraction ≤ 35%, Mini 
Mental score < 20 and the use of statins during the previous 
six months. The selected subjects were submitted to an 
baseline evaluation (basal) that comprised the clinical exam; 
Mini Mental Test; laboratory test profiles including assays 
for glucose, lipids, liver enzymes, creatine phosphokinase 
(CPK), high sensitivity CRP by means of nephelometrics; 
electrocardiogram (ECG), and echodopplercardiogram. 
Vasomotor function was evaluated by means of high 
resolution ultrasound assessment of the brachial artery, 
according to standard guidelines.15,16 The placebo group (PG 
= 23) and the atorvastatin treatment group (TG = 24), were 
assigned by random computer-generated numbers. Placebo 
and atorvastatin (20 mg, donated by Pfizer – Brazilian 
Industry) were used orally over a 30-day period. After this 
time, all patients underwent a second evaluation that included 
the clinical exam and assessments of lipids, enzymes, CRP 
and vasomotor function. The study was approved by the 
Ethical Research Committee of the institution and all 
patients signed an informed consent form.
The sample size was calculated for detecting a difference 
of one-half standard deviation in FMD in the treated group, 
and 20 patients were required for each arm of the study. 
From previous studies in our laboratory, we expected a 
standard deviation of 4%. 
Study Protocol
Endothelium-dependent vasomotor function was 
evaluated through the dilation of the brachial artery, induced 
by reactive hyperemia (FMD); whereas endothelium-
independent dilation was induced by sublingual 5 mg 
isosorbide dinitrate (NTD). Vasoactive medication was 
withheld for at least four half-lives of those drugs. After a 
fasting period of 12 hours, the patients remained at rest for 
30 min, and then they were placed in a supine position in 
a room with a controlled temperature between 23 and 24 
degree Celsius. The brachial artery was evaluated with a 
high-frequency linear transducer from 7 to 12 MHz, using 
an ATL “Medical Systems Company” HDI 500 ultrasound 
system gated to ECG. The evaluation point was above the 
antecubital fossa of the elbow, in the longitudinal plane; 
where image and basal flow were recorded. The hyperemic 
stimuli was induced by pneumatic tourniquet inflated to 
250 mm Hg for five minutes on the arm. After deflation, 
hyperemic velocity was recorded at 15 s, and images were 
recorded at 60 s. After 20 min of rest, with the image 
record, dinitrate was administered and 5 min later the image 
recording was repeated. 
The images recorded with a VCR were later used for 
measurements by an independent observer, using specific 
software that automatically identified artery borders; 
measurements were synchronized to the QRS of the ECG, 
and an average of 6 evaluated segments were used. The 
diameters were expressed in mm, and the diameter variation 
was expressed in percentages.
Statistical Analysis 
The data are presented as means, standard deviations and 
medians. Continuous variables, with normal distribution, 
were compared by Student’s t-test; those variables with 
an asymmetric distribution, in contrast, were compared 
using the Mann-Whitney test, and Wilcoxon test. The 
interactions between sex, age group (< 80 and ≥ 80 years), 
LDL-c (< 160 and ≥ 160 mg/dL), BMI (≤ 25 and > 25 kg/
m2), systolic pressure (< 140 and ≥ 140 mm Hg), diastolic 
pressure (< 90 and ≥ 90 mmHg) and number of risk 
factors (≤ 2 and > 2) were tested by Maentel-Haenzel’s 
x2. Spearman’s correlations were used for intra- and inter-
observer evaluation, and p-values < 0.05 were considered 
statistically significant. The STATA software was also used 
in the analysis.
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RESULTS
The patients were 65-91 years old, with a mean age of 75.8 
± 6.6 years in the placebo group, and 72.0 ± 8.3 years in the 
atorvastatin group. The patients were predominantly women 
(64%). There were no significant differences regarding age, 
sex, race, BMI, risk factors, blood pressure, ejection fraction 
and glucose between the two groups (Table 1).
Prior to treatment, both groups had moderate 
hypercholesterolemia (LDL-c = 155.2 ± 15.7 mg/dL in 
the placebo group vs. 170.1 ± 38.9 mg/dL in the treatment 
group; p = ns), normal HDL and triglycerides. CRP, AST, 
ALT and CPK were also within the normal ranges for both 
groups (Table 2).
After treatment with atorvastatin, there was a reduction 
of 27% in total cholesterol, 42% in LDL-c, 20% in VLDL-c, 
30% in triglycerides (p < 0.05 for all metrics); there was 
also a 12% increase of HDL-c, which was not statistically 
significant (Table 2).
In contrast, there were no significant changes in the 
placebo group (Table 2).
The inflammatory biomarker CRP was not different 
at baseline (0.6 mg/dL vs. 0.5 mg/dL). However, after 30 
days, it increased to 1.1 mg/dL in the placebo group, and 
was reduced to 0.4 mg/dL in the atorvastatin group. That 
final levels of atorvastatin achieved statistically significant 
difference to initial atorvastastin (p=0.02) and to final 
placebo levels (p=0.014) (Figure 1).
There were no significant differences of the flow-
Table 1 - Baseline characteristics
Placebo Atorvastatin 
N 23 24
Age (years) 75.8 ± 6.6 
(65 – 91)
72.0 ± 8.3 
(65 – 90)
Men 8 (35%) 9 (38%)
Women 15 (65%) 15 (62%)
White 7 (30%) 6 (25%)
Non-white 16 (70%) 18 (75%)
BMI (kg/m2) 25.5 ± 3.2 
(17 – 29)
25.2 ± 2.4 
(19 – 29)
Abd. Circ. (cm) 95.8 ± 8.3 
(79 – 112)
94.0 ± 8.6 
(73 – 110)
Risk Factor 3 (2 – 3) 2 (1 – 3)
SBP (mmHg) 157.0 ± 20.2 
(110.0 – 190.0)
150.0 ± 20.7 
(120.0 – 180.0)
DBP(mmHg) 86.0 ± 7.1 
(75.0 – 100.0)
82.0 ± 6.8 
(70.0 – 100.0)
EF (%) 63.6 ± 5.5 
(52.0 – 72.0)
66.0 ± 7.9 
(43.0 – 69.0)
Glucose (mg/dL) 86.3 ± 8.9 
(72.0 – 107.0)
86.6 ± 10.5 
(69.0 – 110.0)
Creatinine (mg/dL) 0.9 ± 0.1 
(0.7 – 1.2)
0.9 ± 0.2 
(0.6 – 1.2)
T4 (ng/dL) 1.0 ± 0.2 
(0.8 – 1.6)
1.1 ± 0.2 
(0.8 – 1.5)
TSH (milli-IU/mL) 2.4 ± 1.4 
(0.8 – 5.3)
2.1 ± 0.7 
(0.6 – 5.3)
BMI: body massa index; Abd. Circ.: abdominal circumference; Risk Fac-
tor: number of risk factors;  SBP: Systolic blood pressure; DBP: Diastolic 
blood pressure EF: ejection fraction . Data presented in absolute values, 
ratios, averages with standard deviations, maximum & minimum values in 
parenthesis. P=NS
Table 2 - Laboratorial profile of subjects before and after treatment 
Placebo (n=23) Atorvastatin n=24)
Initial Final Initial Final
Colesterol “Total” (mg/dL) 231.9±23.4 
(193.0 – 279.0)
222.8±27.6** 
(178.0 – 264.5)
249.8±45.13* 
(199.0 – 386.1)
161.8±30.5** 
(126.3 – 250.4)
LDL-c (mg/dL) 155.2±15.7* 
(132.6 – 198.6)
146.6±24.5** 
(102.0 – 203.6)
170.1±38.9* 
(132.6 – 304.5)
84.9±26.9** 
(50.2 – 173.0)
VLDL-c (mg/dL) 25.3±7.5 
(15.1 – 45.8)
26.7±9.1** 
(16.5 – 53.4)
26.8±12.2 
(11.6 – 58.2)
21.3±8.5** 
(10.0 – 40.9)
HDL-c (mg/dL) 50.9±13.4 
(32.0 – 75.0)
48.8±9.6 
(33.9 – 69.1)
52.9±17.1 
(32.0 – 105.0)
55.7±12.8 
(35.1 – 89.0)
Triglycerides (mg/dL) 161.2±97.6 
(75.7 – 395.0)
162.3±98.3** 
(82.5 – 394.0)
133.0±61.2 
(57.9 – 291.1)
106.6±42.5** 
(49.9 – 204.4)
CRP (mg/dL) 0.6±0.7 
(0.1 – 2.6)
1.1±3.0** 
(0.1 – 14.6)
0.5±0.7 
(0.1 – 3.8)
0.4±0.9** 
(0.1 – 4.5) 
AST (U/L) 25.6±5.8 
(13.0 – 39.0)
26.3±6.3 
(12.0 – 40.0)
27.5±7.0 
(11.0 – 40.0)
28.3±7.7 
(18.0 – 54.0)
ALT (U/L) 18.7±8.5 
(4.3 – 44.0)
19.2±7.9** 
(9.8 – 40.7)
20.8±7.4 
(11.0 – 35.5)
27.9±9.9** 
(10.8 – 52.9)
CPK (U/L) 113.0±75.8 
(35.0 – 346.0)
122.0±68.4 
(45.0 – 332.0)
124.6±46.6 
(57.0 – 246.0)
133.5±62.3 
(40.0 – 258.0)
Values:mean ±SD (minimum and maximum values). AST: aspartate aminotransferase; ALT: alanine aminotransferase; CPK: creatine phosphokinase. p 
(initial)=p value before treatment; p (final)=p value at the end of study. *P<0.05 (between initial conditions): **p<0.05 (between final conditions)
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mediated dilation and nitrate dilation at baseline or after 
4 weeks in either the placebo or atorvastatin group, (Table 
3; Figure 2). The patients presented reduced vasodilatation 
relative to normal controls which is over 8%.
The intra- and inter-observer variation was 0.53% and 
there were very good correlations between inter-observer 
evaluations (r = 0.86 to 0.98 p < 0.001).
Stratified analysis did not reveal significant effects of 
sex, age, level of LDL-c, BMI, systolic pressure, diastolic 
pressure and risk factor co-variables in relation to treatment 
with atorvastatin and vasomotor function.
After treatment, the greatest increase in liver enzymes 
was < 3, and the greatest increase of CPK was < 1.5 times 
the limit; no patients complained of myalgia.
DISCUSSION
We studied a group of elderly individuals, mostly 
women, who were apparently healthy except for moderate 
hypercholesterolemia and stage I systolic hypertension. 
They had a depressed vasodilatory arterial capacity, both 
endothelium-dependent and -independent. With atorvastatin 
treatment, 20 mg daily for 30 days, the arterial dilatory 
function was not restored, despite a significant reduction 
of total cholesterol and LDL-c and a moderate increase 
of HDL-c. The stratified co-variables, such as LDL-c, 
sex, age, a number of risk factors, BMI, systolic and 
diastolic pressure, did not have a significant influence in 
the association of atorvastatin use and vasomotor function. 
There was a significant reduction of the CRP in the treatment 
group relative to the placebo group. The lack of change in 
vasodilatation may be explained by structural or functional 
alterations of the arteries related to senescence itself, such 
as a decrease of synthesis and bioavailability of nitric oxide 
and hardening of the arterial walls.4,8 With aging, arteries 
begin to thicken, and they gradually lose the capacity to 
distend. Studies that evaluated the viscous-elastic properties 
of arterial walls have shown that there are differences 
between the arteries of young and older people, specifically, 
the longitudinal retraction, the circumference increase and 
compliance decrease with age.17-19 Hardening of the arterial 
wall alters the elastic coefficient, which leads to a lower 
capacity of dilatation to stimulus, either by endogenous or 
exogenous nitric oxide.17 Other studies have found larger 
FMD and NTD values, but the limits of the patients’ age 
were below those of the present study.11-16,20,21,24 Several 
studies have reported improvement of vasomotor function 
Figure 1 - Anti-inflammatory effect (hs-CRP levels) of the 4-week treat-
ment with atorvastatin
Table 3 - Brachial artery diameters, flow mediated dilation (FMD) and nitrate dilatation (NTD) before and after treatment 
Placebo (n=23) Atorvastatin ( n=24)
Initial Final Initial Final
Basal (mm) 4.1±0.4 (3.2 – 5.0) 4.0±0.4 (3.2 – 4.9) 4.1±0.7 (3.0 – 5.8) 4.0±0.6 (3.0 – 5.6)
Hyperemia (mm) 4.4±0.4 (3.7 – 5.1) 4.3±0.4 (3.6 – 5.3) 4.2±0.7 (2.9 – 5.7) 4.3±0.7 (3.1 – 6.2)
Pre Nitrate (mm) 4.4±0.4 (3.4 – 5.2) 4.3±0.5 (3.6 – 5.2) 4.1±0.7 (2.9 – 5.9) 4.2±0.7 (3.2 – 5.8)
Nitrate (mm) 4.7±0.5 (3.9 – 6.3) 4.6±0.4 (3.9 – 5.5) 4.6±0.7 (3.4 – 6.4) 4.6±0.8 (3.4 – 6.4)
FMD (%) 7.3±6.1 (0.2 – 17.7) 6.2±6.2 (-4.8 – 23.7) 4.5±5.1 (-3.8 – 18.7) 5.0±5.6 (-5.1 – 18.9)
NTD (%) 8.1±5.4 (1.0 – 21.2) 7.1±4.7 (-1.3 – 21.1) 10.8±7.5 (1.9 – 36.5) 8.6±5.0 (1.4 – 21.6)
() range
Figure 2 - Flow Mediated Dilation (FMD) and Nitrate dilation at pre- and 
post-treatment (4 weeks of placebo or low dose atorvastatin)
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with some interventions, including statins.13,22-24 However, 
studies comparing elderly people to younger ones that 
used atorvastatin for 6 weeks, also reported no restoration 
of vasomotor function.25 Another explanation for no 
amelioration of vasodilator response may be the need for a 
longer treatment period or higher dose of atorvastatin.
The significant reduction of CRP detected in the present 
study emphasizes the possibility of anti-inflammatory action 
of the statins.26,27 This is important because inflammation 
has been consistently observed at different stages of 
atherosclerosis. On the other hand, the presence of CRP has 
been demonstrated in atherosclerotic lesions; additionally, 
high concentrations of inflammation markers, CRP among 
others, in apparently healthy subjects, have been shown to 
be predictive of future vascular events.27,28 The observed 
reduction of lipid and HDL-c levels are in agreement with 
other studies.29-33 It is worth noting that the elderly patients 
in our study presented good tolerance to the treatment, 
considering the absence of clinical manifestations related to 
the atorvastatin use and the non-significant variation of CPK 
and liver enzymes.
Because there is no consensus about treatment of 
dyslipidemia in the elderly; this study allowed for the 
evaluation of reduction levels of lipids and CRP upon 
vasomotor function in elderly patients. Evidently, the 
absence of a significant effect of atorvastatin upon arterial 
dilation does not preclude the use of statins in the elderly 
since reduction of dyslipidemia and inflammation are 
important by themselves, indeed those actions may be 
responsible for the beneficial effects observed with statin 
administration in other studies.13,23,31-33
There are limitations in the present study that are related 
to the selection of the population and the small sample size. 
However, this was intended as a short-term study in which 
clinical outcomes were not evaluated, and sample size was 
calculated only to detect a difference of one-half standard 
deviation between the two groups; this necessitated having 
just 20 patients in each group.
CONCLUSION
Despite a significant reduction in lipids and CRP, 
there were no significant changes in vasomotor function, 
suggesting that intrinsic alterations of the vessel are 
associated with old age.
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